Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Frenkel

Showing results (311-320 of 383) with videos related to

Pageof 39
Sort By:
Journal of Virology|July 15, 2005
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virusNicole H Tobin, Gerald H Learn, Sarah E Holte, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|March 1, 1997
Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected womenA J Melvin, S K Burchett, D H Watts, et al.
Science (New York, N.Y.)|November 22, 2008
Dynamic proteomics of individual cancer cells in response to a drugA A Cohen, N Geva-Zatorsky, E Eden, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
AIDS Research and Human Retroviruses|November 6, 2009
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV preventionBenjamin H Chi, Giovanina M Ellis, Namwinga Chintu, et al.
Journal of Human Virology|March 22, 2002
Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assayM L Villahermosa, I Beck, L Pérez-Alvarez, et al.
Plos One|September 27, 2022
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at termCeejay L Boyce, Ingrid A Beck, Sheila M Styrchak, et al.
The Journal of Infectious Diseases|April 1, 1997
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1L M Frenkel, M K Cowles, D E Shapiro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Plos Medicine|March 28, 2018
Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohortJoanne D Stekler, Ross Milne, Rachel Payant, et al.
Pageof 39

Showing results (311-320 of 383) with videos related to

Sort By:
Pageof 39
Journal of Virology|July 15, 2005
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: expression of archival virus and replication of virusNicole H Tobin, Gerald H Learn, Sarah E Holte, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|March 1, 1997
Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected womenA J Melvin, S K Burchett, D H Watts, et al.
Science (New York, N.Y.)|November 22, 2008
Dynamic proteomics of individual cancer cells in response to a drugA A Cohen, N Geva-Zatorsky, E Eden, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
AIDS Research and Human Retroviruses|November 6, 2009
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV preventionBenjamin H Chi, Giovanina M Ellis, Namwinga Chintu, et al.
Journal of Human Virology|March 22, 2002
Detection and quantification of multiple drug resistance mutations in HIV-1 reverse transcriptase by an oligonucleotide ligation assayM L Villahermosa, I Beck, L Pérez-Alvarez, et al.
Plos One|September 27, 2022
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at termCeejay L Boyce, Ingrid A Beck, Sheila M Styrchak, et al.
The Journal of Infectious Diseases|April 1, 1997
Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1L M Frenkel, M K Cowles, D E Shapiro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Plos Medicine|March 28, 2018
Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohortJoanne D Stekler, Ross Milne, Rachel Payant, et al.
Pageof 39